Biotinylated Human CD200/OX-2 Protein
Catalog No: CD200-HB002
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human CD200/OX-2 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Gln31-Gly232 (UniProt accession: P41217-1).
Product Details
- Molecular Aliases
- CD200; MOX1; MOX2; My033; MRC; OX-2; OX2
- Protein Length
- Gln31-Gly232
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 25.35 kDa. Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human CD200 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human CD200 is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human CD200, His Avi tag at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Human CD200 R1, hFc Tag with the EC50 of 5.5ng/ml determined by ELISA. (QC Test)
Loaded Biotinylated Human CD200, His-Avi tag on Steptavidin-Biosensor can bind Human CD200 R1, hFc Tag with an affinity constant of 0.30 nM as determined in BLI assay (Gator® Prime).
Background
CD200 and its receptors are highly expressed in the lung, on epithelial cells and leukocytes, and emerging evidence links dysregulation of the CD200 pathway with asthma. Moreover, pharmacological modulation of CD200 receptors was shown to improve clinical and inflammatory outcomes of preclinical asthma models.
References
- Ngwa C, Liu F. CD200-CD200R signaling and diseases: a potential therapeutic target? Int J Physiol Pathophysiol Pharmacol. 2019 Dec 15;11(6):297-309. PMID: 31993106; PMCID: PMC6971504.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.